On January 13, 2025, IceCure Medical Ltd. issued a letter to shareholders from CEO Eyal Shamir, outlining key achievements for 2024. Preliminary unaudited results indicated that ProSense® system and disposable probe sales increased to $3.19 million for the year ended December 31, 2024, up from $2.96 million in 2023. Notably, the North American market demonstrated significant growth with a 42% increase in sales compared to 2023.
The company completed its 10-year ICE3 study, reporting a 96.3% recurrence-free rate and 100% patient and physician satisfaction, with results published in the Annals of Surgical Oncology. Interim results from the ICESECRET kidney cancer study showed an 88.7% recurrence-free rate, presented at the Israeli Urological Association Conference in December 2024. These clinical validations underscore the efficacy of ProSense® across multiple indications.
IceCure also fortified its intellectual property, receiving four new patents in the U.S., Japan, and Europe for its next-generation multi-probe cryoablation system, cryogenic pump, and cryogenic flow control technology. Furthermore, the FDA granted regulatory clearance for the next-generation XSense™ Cryoablation System with CryoProbes for existing indications. The company's cash and cash equivalents balance was approximately $7.5 million as of December 31, 2024. The Board of Directors was expanded to include Vic Lee, the controlling shareholder.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.